NCT06967194 Early Beta Blocker Administration in STEMI Patients With SCAI B Status
| NCT ID | NCT06967194 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Condition | ST Segment Elevation Myocardial Infarction (STEMI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-05-21 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-05-21 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit. When patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups. During the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations. The main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization. * Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and/or hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary refill, preserved mental status, and adequate urine output \>0.5 mL/kg/hour). * Age 18 years or older. * Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations. Exclusion Criteria: * Pregnancy. * Inability to provide informed consent. * Evidence of pulmonary edema. * Bradycardia (heart rate \<60 beats per minute). * PR interval \>240 milliseconds. * Second- or third-degree atrioventricular (AV) block. * Active asthma. * Known hypersensitivity to metoprolol.
Contact & Investigator
Yishay Szekely, MD
PRINCIPAL INVESTIGATOR
Tel-Aviv Sourasky Medical Center
Frequently Asked Questions
Who can join the NCT06967194 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ST Segment Elevation Myocardial Infarction (STEMI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06967194 currently recruiting?
Yes, NCT06967194 is actively recruiting participants. Contact the research team at shirfrydman@gmail.com for enrollment information.
Where is the NCT06967194 trial being conducted?
This trial is being conducted at Tel Aviv, Israel.
Who is sponsoring the NCT06967194 clinical trial?
NCT06967194 is sponsored by Tel-Aviv Sourasky Medical Center. The principal investigator is Yishay Szekely, MD at Tel-Aviv Sourasky Medical Center. The trial plans to enroll 200 participants.